Cornerstone Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Cornerstone Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	–	Sell	-1,020,088	Closed	-$40M	–	58
2013 Q2	$40M	Buy	+1,020,088	New	+$39.7M	1.32%	35

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Allianz Asset Management Munich, Germany $112B AUM 36.28% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return

Cornerstone Capital Management's TEVA Position: Q3 2013 in Review

Cornerstone Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q3 2013, closing a stake of 1,020,088 shares — an estimated $40M sold.

Cornerstone Capital Management first reported a position in TEVA in Q2 2013 and held it in 1 quarter. The position peaked at $40M in Q2 2013. 705 funds tracked by Wall St. Rank hold TEVA as of Q3 2013.

Cornerstone Capital Management reported no remaining Teva Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
Cornerstone Capital Management sold 1,020,088 Teva Pharmaceuticals shares in Q3 2013, an estimated $40M.
Cornerstone Capital Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 1 quarter.
Cornerstone Capital Management's Teva Pharmaceuticals position peaked at $40M in Q2 2013.
705 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2013.

Based on Cornerstone Capital Management's 13F filing for Q3 2013, filed 12 Nov 2013.